Immunohistochemistry Findings are useful in diagnosing Metas
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Cutaneous squamous cell carcinoma (SCC) is the second most common type of skin cancer. Only 2% to 5% of SCCs metastasize; however, those do carry a poor prognosis. Immunohistochemistry (IHC) is widely used by pathologists to characterize skin cancers and provide clinically useful information. A Study was conducted to evaluate the potential prognostic associations between IHC findings and metastasis in SCC.

Searches were conducted in MEDLINE via PubMed. 653 articles were returned and screened, which ultimately left 31 for inclusion in our manuscript.

Results:
--31 articles analyzed in this review included a discussion of the expression of a particular IHC marker and the associated risk of metastasis and/or clinical utility of IHC markers in SCC, especially metastatic SCC.
--Markers that had several or more studies supporting clinical utility were E-cadherin, podoplanin, CD8+ T cells, PD-L1, epidermal growth factor receptor, and Cyclin D1.

In particular, SCC immunohistochemistry profiling can be useful in selective cases where providing prognosis remains difficult and when identifying possible therapeutic targets for high-risk or metastatic tumors.

Source: https://journals.lww.com/dermatologicsurgery/Abstract/2021/03000/The_Correlation_Between_Immunohistochemistry.1.aspx
Like
Comment
Share